Galapagos Initiates IBD Therapy Trial on Ulcerative Colitis Patients

Galapagos Initiates IBD Therapy Trial on Ulcerative Colitis Patients
Galapagos NV has started a phase 2 Proof-of-Concept study to evaluate a potential novel therapy, a GPR84 inhibitor called GLPG1205 that is being studied in patients who suffer from ulcerative colitis. The experimental therapy has been developed as part of a target discovery platform designed by Galapagos and is fully proprietary, according to a company press release. The phase 2 Proof-of-Concept

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *